Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) EBT (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed EBT for 16 consecutive years, with -$3.2 million as the latest value for Q4 2025.

  • Quarterly EBT fell 643.05% to -$3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$57.4 million through Dec 2025, down 391.95% year-over-year, with the annual reading at -$57.4 million for FY2025, 391.95% down from the prior year.
  • EBT for Q4 2025 was -$3.2 million at Harvard Bioscience, down from -$1.1 million in the prior quarter.
  • The five-year high for EBT was $3.4 million in Q2 2022, with the low at -$50.8 million in Q1 2025.
  • Average EBT over 5 years is -$4.0 million, with a median of -$1.1 million recorded in 2023.
  • Peak annual rise in EBT hit 641.3% in 2022, while the deepest fall reached 10522.22% in 2022.
  • Over 5 years, EBT stood at $1.1 million in 2021, then tumbled by 178.87% to -$892000.0 in 2022, then fell by 23.65% to -$1.1 million in 2023, then soared by 153.49% to $590000.0 in 2024, then tumbled by 643.05% to -$3.2 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$3.2 million, -$1.1 million, and -$2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.